fda warning letter glp-1 october 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines Trends In FDA FY 2025

Implication: Many guidelines recommend against using GLP-1 drugs in people with prior pancreatitis unless benefits strongly outweigh risks and there is close monitoring

Many celebrities have shared their successful weight loss journeys using these weight loss injections

Scheme 31

GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Zepbound, liraglutide/Saxenda) are not DEA-scheduled drugs

Effect of drink temperature on antropyloroduodenal motility and gastric electrical activity in humans

Monitoring should include assessment of gastrointestinal tolerance, hydration status, renal function, limb measurements, pain levels, mobility, and quality of life indicators